$NGNE
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Rachel L. McMinn
CEO
107
Employees
$19.05
Current Price
$309.94M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $225,622.18 | 10,842 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 7 | $346,148.26 | 15,642 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 7 | $346,148.26 | 15,642 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 7 | $346,148.26 | 15,642 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | Cobb Stuart Chief Scientific Officer | Sale | 3,991 | $20.41 | $81,456.31 | View Details |
| Mar 13, 2026 | Cobb Stuart Chief Scientific Officer | Sale | 2,658 | $21.34 | $56,721.72 | View Details |
| Mar 13, 2026 | Cobb Stuart Chief Scientific Officer | Sale | 148 | $22.08 | $3,267.84 | View Details |
| Mar 13, 2026 | Cvijic Christine Mikail President and CFO | Sale | 2,387 | $20.42 | $48,748.27 | View Details |
| Mar 13, 2026 | Cvijic Christine Mikail President and CFO | Sale | 1,395 | $21.25 | $29,636.91 | View Details |
| Mar 13, 2026 | Cvijic Christine Mikail President and CFO | Sale | 263 | $22.02 | $5,791.13 | View Details |
| Feb 27, 2026 | Cvijic Christine Mikail President and CFO | Sale | 4,800 | $25.11 | $120,526.08 | View Details |
1 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$1.24
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
No past earnings data available